What is camoteskimab studying for moderate-to-severe atopic dermatitis?

Camoteskimab is being studied to evaluate its effects on adults with moderate-to-severe atopic dermatitis. The study compares different doses of camoteskimab to a placebo to understand its impact on eczema severity and itch. Apollo Therapeutics Ltd is leading this research to explore new treatment options for this skin condition.

Who may be eligible for this atopic dermatitis clinical trial?

Adults aged 18 to 65 with moderate-to-severe atopic dermatitis lasting at least one year may be eligible. Participants should have significant eczema involvement and itch, and may include those who have not responded well to previous topical or biologic treatments. Both men and women can participate. Please review eligibility criteria for more details.

Is there any cost to participate in this atopic dermatitis clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. However, personal travel expenses and other costs may vary and are not guaranteed to be covered. Participants should plan accordingly for any associated travel or accommodation expenses.

Actively Recruiting

Phase 2

Age: 18Years - 65Years

All Genders

ID07599813

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

Led by Apollo Therapeutics Ltd · Updated on 2026-06-02

280

Participants Needed

Research Sites

26 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating camoteskimab, a drug being studied in adults with moderate-to-severe atopic dermatitis. This phase 2b study is multicenter, randomized, double-blind, and placebo-controlled, aiming to assess the drugs effects compared to placebo. Participants include those who have not been treated before and those who have had an inadequate response to previous biologic therapies. The study has two parts Part 1 is a 24-week period where participants are randomly assigned to one of four groups receiving one of three doses of camoteskimab or a placebo, all given by subcutaneous injection. In Part 2, an extension period, all participants will receive camoteskimab. This design allows researchers to compare the drug doses with placebo initially and then provide treatment to all participants. Participants will be involved for at least 24 weeks in the placebo-controlled phase and beyond during the extension. They will undergo assessments including the Eczema Area and Severity Index EASI, Investigator Global Assessment IGA, and peak itch ratings. Researchers will measure changes in eczema severity, itch intensity, and skin condition over time. Safety and adherence will be monitored throughout the study period to evaluate the drugs effects and tolerability.

CONDITIONS

Brief Title

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

Who Can Participate

Age: 18Years - 65Years

All Genders

Eligibility Criteria

You may qualify if you...

Age 18 to 65 years at the time of informed consent
Chronic atopic dermatitis for at least 1 year confirmed by clinical diagnosis
Moderate-to-severe atopic dermatitis defined by: IGA score of 3 or higher at screening and baseline
Atopic dermatitis affecting 10% or more of body surface area at screening and baseline
EASI score of 16 or higher at screening and baseline
Peak pruritus numerical rating scale (PP-NRS) score of 4 or higher at baseline with at least 4 daily scores out of 7 days
Candidates for systemic therapy due to inadequate response to topical treatments or medical inadvisability of topical treatments
Use of contraception consistent with local regulations for clinical studies
Signed informed consent provided

You will not qualify if you...

Severe illness or psychiatric conditions such as severe depression or suicidal attempt in past 10 years judged unsuitable for the study
Active infection requiring systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before baseline
Other active skin diseases or infections that affect atopic dermatitis evaluation
Significant flares of atopic dermatitis within 4 weeks before screening
Severe comorbidities requiring systemic steroids or frequent monitoring
Clinically significant ECG abnormalities affecting QTc interval assessment
Severe uncontrolled seasonal or allergic rhinitis, asthma, or other atopic diseases
Use of medicated moisturizers by prescription within 2 weeks prior to baseline
Active HIV, hepatitis B, hepatitis C (unless cured), or tuberculosis
Live or attenuated live vaccine within 6 weeks before screening
Major surgery within 8 weeks before baseline or planned during the study
Known immune deficiency or immunocompromised state
Malignancy diagnosed within 5 years except certain skin or cervical cancers
Previous exposure to anti-IL-18 therapy
Known allergy to any component of the investigational product
Recent use of specific medications affecting atopic dermatitis including certain biologics, JAK inhibitors, topical and systemic treatments within specified time frames
Pregnancy, breastfeeding, or trying to conceive
Unlikely to adhere to treatment or protocol as judged by investigator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here